文献速递头颈部肿瘤放疗放疗物理与技术

MitoTam 诱导铁死亡并增加头颈癌细胞放射敏感性

MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells.
PubMed 文献 · Radiother Oncol · 2024-08-24

研究在放射敏感(UT-SCC-40)与放射抵抗(UT-SCC-5)头颈鳞癌细胞中评估线粒体靶向他莫昔芬类似物 MitoTam 的作用。MitoTam 增加活性氧、细胞死亡、线粒体膜电位破坏和脂质过氧化,且可被铁死亡抑制剂 ferrostatin-1 逆转,提示诱导铁死亡。MitoTam 预处理后放疗较单用放疗或单用 MitoTam 产生超相加的残留 DNA 损伤,放射抵抗细胞因内在抗氧化能力较高而对 MitoTam 较不敏感。

要点

  • MitoTam 在放射敏感与放射抵抗头颈鳞癌细胞中均诱导铁死亡。
  • 放射抵抗细胞因内在抗氧化能力较高而对 MitoTam 较不敏感。
  • MitoTam 预处理后放疗较单用放疗或单用 MitoTam 产生超相加的残留 DNA 损伤。

核心结论

  • MitoTam 在头颈鳞癌细胞中诱导铁死亡,可能用于克服放射抵抗细胞升高的抗氧化能力并使其对放疗增敏。
  • 作者认为 MitoTam 后接放疗可能成为放射抵抗癌症有前景的有效治疗。

研究设计与样本

  • 体外细胞研究,使用放射敏感(UT-SCC-40)与放射抵抗(UT-SCC-5)头颈鳞癌细胞系。
  • 评估 MitoTam 处理后的细胞活力、活性氧产生、线粒体膜电位破坏和脂质过氧化。
  • 使用铁死亡抑制剂 ferrostatin-1(fer-1)评估铁死亡特异性。
  • 评估总抗氧化能力与对叔丁基过氧化氢的敏感性以评估活性氧反应。
  • 使用 53BP1 染色评估 MitoTam 处理后的放射敏感性。

主要发现

  • MitoTam 处理后在两种细胞系中均增加活性氧、细胞死亡、线粒体膜电位破坏和脂质过氧化。
  • fer-1 可阻止 MitoTam 对细胞死亡、膜电位和脂质过氧化的不良影响,提示诱导铁死亡。
  • 放射抵抗头颈鳞癌细胞因内在抗氧化能力较高而对 MitoTam 作用较不敏感。
  • MitoTam 预处理后放疗较单用放疗或单用 MitoTam 产生超相加的残留 DNA 损伤,以 53BP1 灶表示。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiotherapy (RT) is an integral treatment part for patients with head and neck squamous cell carcinoma (HNSCC), but radioresistance remains a major issue. Here, we use MitoTam, a mitochondrially targeted analogue of tamoxifen, which we aim to stimulate ferroptotic cell death with, and sensitize radioresistant cells to RT. MATERIALS AND METHODS: We assessed viability, reactive oxygen species (ROS) production, disruption of mitochondrial membrane potential, and lipid peroxidation in radiosensitive (UT-SCC-40) and radioresistant (UT-SCC-5) HNSCC cells following MitoTam treatment. To assess ferroptosis specificity, we used the ferroptosis inhibitor ferrostatin-1 (fer-1). Also, total antioxidant capacity and sensitivity to tert-butyl hydroperoxide were evaluated to assess ROS-responses. 53BP1 staining was used to assess radiosensitivity after MitoTam treatment. RESULTS: Our data revealed increased ROS, cell death, disruption of mitochondrial membrane potential, and lipid peroxidation following MitoTam treatment in both cell lines. Adverse effects of MitoTam on cell death, membrane potential and lipid peroxidation were prevented by fer-1, indicating induction of ferroptosis. Radioresistant HNSCC cells were less sensitive to the effects of MitoTam due to intrinsic higher antioxidant capacity. MitoTam treatment prior to RT led to superadditive residual DNA damage expressed by 53BP1 foci compared to RT or MitoTam alone. CONCLUSION: MitoTam induced ferroptosis in HNSCC cells, which could be used to overcome the elevated antioxidant capacity of radioresistant cells and sensitize such cells to RT. Treatment with MitoTam followed by RT could therefore present a promising effective therapy of radioresistant cancers. STATEMENT OF SIGNIFICANCE: Radiotherapy is applied in the treatment of a majority of cancer patients. Radioresistance due to elevated antioxidant levels can be overcome by promoting ferroptotic cell death combining ROS-inducing drug MitoTam with radiotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Reinema FV, Hudson N, Adema GJ, et al. MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells. Radiother Oncol. 2024. PMID: 39186982. doi:10.1016/j.radonc.2024.110503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。